国产日产欧美精品-亚洲国产综合久久精品-色综合色国产热无码一-亚洲欧美日本国产,免费观看一区二区三区_在线观看片A免费不卡观看_亚洲а∨天堂久久精品_99久无码中文字幕一本久道

青旗(上海)生物技術發(fā)展有限公司
中級會員 | 第5年

4006560232

當前位置:青旗(上海)生物技術發(fā)展有限公司>>細胞庫>>細胞系>> 人肺鱗癌細胞SK-MES-1

人肺鱗癌細胞SK-MES-1

參  考  價面議
具體成交價以合同協議為準

產品型號

品       牌其他品牌

廠商性質生產商

所  在  地上海市

更新時間:2021-05-21 10:19:53瀏覽次數:817次

聯系我時,請告知來自 化工儀器網
同類優(yōu)質產品更多>
供貨周期 現貨 規(guī)格 T25培養(yǎng)瓶x1 1.5ml凍存管x2
貨號 BFN60800660 應用領域 醫(yī)療衛(wèi)生,生物產業(yè)
主要用途 僅供科研
青旗(上海)生物技術發(fā)展有限公司,總部位于上海浦東新區(qū),依托本地高校資源,逐步發(fā)展成為以生物技術為主的研發(fā)、生產、培訓為一體的綜合化產業(yè)平臺,在標準化細胞庫建立及細胞藥物前端模型方面成果顯著。公司生產經營原代細胞、細胞系、ELISA試劑盒、感受態(tài)細胞和HPLC檢測等科研產品與服務。我們秉承對用戶負責的態(tài)度,以對科研的高度嚴謹,以嚴格的質量控制,為廣大生物醫(yī)學科研用戶提供更優(yōu)質的服務!

細胞名稱

人肺鱗癌細SK-MES-1                  

img1

貨物編碼

BFN60800660

產品規(guī)格

T25培養(yǎng)x1

1.5ml凍存x2

細胞數量

1x10^6

1x10^6

保存溫度

37

-198

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研用途                1類

 

培養(yǎng)體系

DMEM高糖培養(yǎng)基Hyclone+10%胎牛血清Gibco+1%雙抗Hyclone

培養(yǎng)溫度

37

二氧化碳濃度

5%

簡介

人肺鱗癌細SK-MES-1細胞源于一65歲患有肺鱗狀細胞癌的白人男性,自轉移性胸腔積液分離而來。由青旗(上海)生物技術發(fā)展有限公司2018年引種ATCCHTB-58)。

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: MD Anderson Cell Lines Project.

From: Memorial Sloan Kettering Cancer Center; New York; USA.

Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2009-091.

Doubling time: ~50 hours (DSMZ).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

STR信息

AmelogeninX,YCSF1PO12;D13S31711D16S53913;D18S5117;D19S43314;D21S1129,30;D2S133819D3S135816;D5S81811D7S8208;D8S117913,14FGA20,24TH016,9.3TPOX8;vWA14;

參考文獻

DOI=10.1007/978-1-4757-1647-4_5

Fogh J., Trempe G.L.

New human tumor cell lines.

(In) Human tumor cells in vitro; Fogh J. (eds.); pp.115-159; Springer; New York (1975)

 

PubMed=833871; DOI=10.1093/jnci/58.2.209

Fogh J., Wright W.C., Loveless J.D.

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

J. Natl. Cancer Inst. 58:209-214(1977)

 

PubMed=6935474; DOI=10.1093/jnci/66.2.239

Wright W.C., Daniels W.P., Fogh J.

Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.

J. Natl. Cancer Inst. 66:239-247(1981)

 

PubMed=7017212; DOI=10.1093/jnci/66.6.1003

Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.

HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.

J. Natl. Cancer Inst. 66:1003-1012(1981)

 

PubMed=2990217

Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M.

Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.

Am. J. Pathol. 119:361-366(1985)

 

PubMed=4005855

Kyoizumi S., Akiyama M., Kouno N., Kobuke K., Hakoda M., Jones S.L., Yamakido M.

Monoclonal antibodies to human squamous cell carcinoma of the lung and their application to tumor diagnosis.

Cancer Res. 45:3274-3281(1985)

 

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

 

PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)

 

PubMed=8385084; DOI=10.1111/j.1349-7006.1993.tb02851.x

Suzuki S., Takahashi T., Nakamura S., Koike K., Ariyoshi Y., Takahashi T., Ueda R.

Alterations of integrin expression in human lung cancer.

Jpn. J. Cancer Res. 84:168-174(1993)

 

PubMed=7736387; DOI=10.1002/1097-0142(19950515)75:10<2442::AID-CNCR2820751009>3.0.CO;2-Q

Campling B.G., Sarda I.R., Baer K.A., Pang S.C., Baker H.M., Lofters W.S., Flynn T.G.

Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer.

Cancer 75:2442-2451(1995)

 

PubMed=12794755; DOI=10.1002/ijc.11184

Endoh H., Yatabe Y., Shimizu S., Tajima K., Kuwano H., Takahashi T., Mitsudomi T.

RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication.

Int. J. Cancer 106:45-51(2003)

 

PubMed=14581340

Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., Inazawa J.

TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers.

Clin. Cancer Res. 9:4705-4713(2003)

 

PubMed=15746151; DOI=10.1093/hmg/ddi092

Izumi H., Inoue J., Yokoi S., Hosoda H., Shibata T., Sunamori M., Hirohashi S., Inazawa J., Imoto I.

Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.

Hum. Mol. Genet. 14:997-1007(2005)

 

PubMed=18083107; DOI=10.1016/j.cell.2007.11.025

Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Cell 131:1190-1203(2007)

 

PubMed=19472407; DOI=10.1002/humu.21028

Blanco R., Iwakawa R., Tang M., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

A gene-alteration profile of human lung cancer cell lines.

Hum. Mutat. 30:1199-1206(2009)

 

PubMed=20164919; DOI=10.1038/nature08768

Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=22460905; DOI=10.1038/nature11003

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

 

PubMed=24002593; DOI=10.1038/bjc.2013.452

Wu D., Pang Y., Wilkerson M.D., Wang D., Hammerman P.S., Liu J.S.

Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity.

Br. J. Cancer 109:1599-1608(2013)

 

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

 

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

 

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005

Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

 

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

 

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

驗收細胞注意事 

1、收到人肺鱗癌細SK-MES-1,請查看瓶子是否有破裂,培養(yǎng)基是否漏出,是否渾濁,如有請盡快聯系。 

2、收到人肺鱗癌細SK-MES-1 ,如包裝完好,請在顯微鏡下觀察細胞。,由于運輸過程中的問題,細胞培養(yǎng)瓶中的貼壁細胞有可能從瓶壁中脫落下來,顯微鏡下觀察會出現細胞懸浮的情況,出現此狀態(tài)時,請不要打開細胞培養(yǎng)瓶,應立即將培養(yǎng)瓶置于細胞培養(yǎng)箱里靜 3-5 小時左右,讓細胞先穩(wěn)定下,再于顯微鏡下觀察,此時多數細胞會重新貼附于瓶壁。如細胞仍不能貼壁,請用臺盼藍染色法鑒定細胞活力,如臺盼藍染色證實細胞活力正常請按懸浮細胞的方法處理。 

3、收到人肺鱗癌細SK-MES-1后,請鏡下觀察細胞,用恰當方式處理細胞。若懸浮的細胞較多,請離心收集細胞,接種到一個新的培養(yǎng)瓶中。棄掉原液,使用新鮮配制的培養(yǎng)基,使用進口胎牛血清。剛接到細胞,若細胞不多 血清濃度可以加 15%去培養(yǎng)。若細胞迏 80% ,血清濃度還是 10 

4、收到人肺鱗癌細SK-MES-1時如無異常情 ,請在顯微鏡下觀察細胞密度,如為貼壁細胞,未超80%匯合度時,將培養(yǎng)瓶中培養(yǎng)基吸出,留 5-10ML 培養(yǎng)基繼續(xù)培養(yǎng):超 80%匯合度時,請按細胞培養(yǎng)條件傳代培養(yǎng)。如為懸浮細胞,吸出培養(yǎng)液,1000 /分鐘離 3 分鐘,吸出上清,管底細胞用新鮮培養(yǎng)基懸浮細胞后移回培養(yǎng)瓶 

5、將培養(yǎng)瓶置 37培養(yǎng)箱中培養(yǎng),蓋子微微擰松。吸出的培養(yǎng)基可以保存在滅菌過的瓶子里,存放 4冰箱,以備不時之需。 

6、24 小時后,細胞形態(tài)已恢復并貼滿瓶壁,即可傳代。(貼壁細胞)將培養(yǎng)瓶里的培養(yǎng)基倒去, 3-5ml(以能覆蓋細胞生長面為準PBS  Hanks液洗滌后棄去。 0.5-1ml 0.25% EDTA 的胰酶消化,消化時間以具體細胞為準,一 1-3 分鐘,不超 5 分鐘。可以放37培養(yǎng)箱消化。輕輕晃動瓶壁,見細胞脫落下來,加 3-5ml 培養(yǎng)基終止消化。用移液管輕輕吹打瓶壁上的細胞,使之*脫落,然后將溶液吸入離心管內離心,1000rpm/5min。棄上清,視細胞數量決定分瓶數,一般一傳二,如細胞量多可一傳三,有些細胞不易傳得過稀,有些生長較快的細胞則可以多傳幾瓶,以具體細胞和經驗為準。(懸浮細胞)用移液管輕輕吹打瓶壁,直接將溶液吸入離心管離心即可。 

7、貼壁細 ,懸浮細胞。嚴格無菌操作。換液時,換新的細胞培養(yǎng)瓶和換新鮮的培養(yǎng)液,375%CO2 培養(yǎng)。

 

特別提醒 原瓶中培養(yǎng)基不宜繼續(xù)使用,請更換新鮮培養(yǎng)基培養(yǎng)。

 青旗(上海)生物技術發(fā)展有限公司,總部位于上海浦東新區(qū),依托本地高校資源,逐步發(fā)展成為以生物技術為主的研發(fā)、生產、培訓為一體的綜合化產業(yè)平臺,在標準化細胞庫建立及細胞藥物前端模型方面成果顯著。公司生產經營原代細胞、細胞系、ELISA試劑盒、感受態(tài)細胞和HPLC檢測等科研產品與服務。我們秉承對用戶負責的態(tài)度,以對科研的高度嚴謹,以嚴格的質量控制,為廣大生物醫(yī)學科研用戶提供更優(yōu)質的服務!

 

 

會員登錄

×

請輸入賬號

請輸入密碼

=請輸驗證碼

收藏該商鋪

X
該信息已收藏!
標簽:
保存成功

(空格分隔,最多3個,單個標簽最多10個字符)

常用:

提示

X
您的留言已提交成功!我們將在第一時間回復您~
撥打電話
在線留言
巍山| 铜陵市| 德令哈市| 格尔木市| 吉隆县| 家居| 垫江县| 通山县| 华宁县| 汝州市| 九龙坡区| 聊城市| 读书| 广南县| 依兰县| 莆田市| 延庆县| 思南县| 新丰县| 尉氏县| 晋江市| 成都市| 涟水县| 德保县| 涡阳县| 上高县| 沾益县| 南宫市| 华亭县| 岳池县| 乌拉特中旗| 漳浦县| 阿拉善左旗| 玛多县| 夏津县| 阳新县| 资中县| 安岳县| 图木舒克市| 八宿县| 青田县|